A limited sampling strategy for cyclophosphamide pharmacokinetics. 1989

M J Egorin, and A Forrest, and C P Belani, and M J Ratain, and J S Abrams, and D A Van Echo
Division of Developmental Therapeutics, University of Maryland Cancer Center, Baltimore, Maryland 21201.

A limited sampling strategy was developed to estimate the total area under the curve of plasma cyclophosphamide concentrations versus time (AUC). The strategy was developed with a training set consisting of 29 pharmacokinetic studies in 16 patients who received 1-h i.v. infusions of cyclophosphamide at a dosage of 1000 mg/m2. The strategy was developed by applying stepwise forward multiple regression analysis to cyclophosphamide concentrations observed at each time in the training set (independent variables) versus the AUC (dependent variable). It was confirmed by applying stepwise backward elimination regression analysis to the same data set. The final sampling strategy, which utilized three time points, was: AUC = 40.18C24 + 8.79C4 + 0.83C1 - 28 (dosage/1000), where C24, C4, and C1 represent plasma cyclophosphamide concentrations at 24, 4, and 1 h, respectively, and the dosage is in mg/m2 (r = 0.98). The strategy was validated prospectively with a test data set consisting of 14 pharmacokinetic studies in 11 patients who received 1-h i.v. infusions of cyclophosphamide at dosages of 300, 600, or 1200 mg/m2. The strategy proved highly predictive, with correlation coefficient between predicted and actual AUC of 0.94. The strategy also proved unbiased, with mean percentage of error (+/- SE) of 3.3 +/- 3.6%, and precise, with mean absolute percentage of error of 9.3 +/- 2.7%. The sampling strategy developed is being used in a multiinstitution trial of cyclophosphamide in an effort to relate cyclophosphamide pharmacokinetics, as expressed by AUC, with the toxic or therapeutic pharmacodynamic responses of the drug.

UI MeSH Term Description Entries
D003520 Cyclophosphamide Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. (+,-)-2-(bis(2-Chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-Oxide Monohydrate,B-518,Cyclophosphamide Anhydrous,Cyclophosphamide Monohydrate,Cyclophosphamide, (R)-Isomer,Cyclophosphamide, (S)-Isomer,Cyclophosphane,Cytophosphan,Cytophosphane,Cytoxan,Endoxan,NSC-26271,Neosar,Procytox,Sendoxan,B 518,B518,NSC 26271,NSC26271
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D012509 Sarcoma A connective tissue neoplasm formed by proliferation of mesodermal cells; it is usually highly malignant. Sarcoma, Epithelioid,Sarcoma, Soft Tissue,Sarcoma, Spindle Cell,Epithelioid Sarcoma,Epithelioid Sarcomas,Sarcomas,Sarcomas, Epithelioid,Sarcomas, Soft Tissue,Sarcomas, Spindle Cell,Soft Tissue Sarcoma,Soft Tissue Sarcomas,Spindle Cell Sarcoma,Spindle Cell Sarcomas
D012983 Soft Tissue Neoplasms Neoplasms of whatever cell type or origin, occurring in the extraskeletal connective tissue framework of the body including the organs of locomotion and their various component structures, such as nerves, blood vessels, lymphatics, etc. Neoplasm, Soft Tissue,Neoplasms, Soft Tissue,Soft Tissue Neoplasm
D013997 Time Factors Elements of limited time intervals, contributing to particular results or situations. Time Series,Factor, Time,Time Factor

Related Publications

M J Egorin, and A Forrest, and C P Belani, and M J Ratain, and J S Abrams, and D A Van Echo
January 1995, Cancer chemotherapy and pharmacology,
M J Egorin, and A Forrest, and C P Belani, and M J Ratain, and J S Abrams, and D A Van Echo
January 1999, Cancer chemotherapy and pharmacology,
M J Egorin, and A Forrest, and C P Belani, and M J Ratain, and J S Abrams, and D A Van Echo
March 1994, Annals of oncology : official journal of the European Society for Medical Oncology,
M J Egorin, and A Forrest, and C P Belani, and M J Ratain, and J S Abrams, and D A Van Echo
October 1987, Cancer treatment reports,
M J Egorin, and A Forrest, and C P Belani, and M J Ratain, and J S Abrams, and D A Van Echo
May 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
M J Egorin, and A Forrest, and C P Belani, and M J Ratain, and J S Abrams, and D A Van Echo
September 2014, International journal of antimicrobial agents,
M J Egorin, and A Forrest, and C P Belani, and M J Ratain, and J S Abrams, and D A Van Echo
January 2017, International journal of clinical pharmacology and therapeutics,
M J Egorin, and A Forrest, and C P Belani, and M J Ratain, and J S Abrams, and D A Van Echo
August 2007, Therapeutic drug monitoring,
M J Egorin, and A Forrest, and C P Belani, and M J Ratain, and J S Abrams, and D A Van Echo
May 2024, Therapeutic drug monitoring,
M J Egorin, and A Forrest, and C P Belani, and M J Ratain, and J S Abrams, and D A Van Echo
July 1988, Cancer research,
Copied contents to your clipboard!